Antiplatelet agent, P2Y12 antagonist
ACP as part of CHAMP pathway: Adjunctive therapy to support thrombolysis in ST elevation myocardial infarction
ACP as part of CHAMP pathway
Not authorized in pediatrics
Irreversibly blocks the P2Y12 component on platelet surfaces, preventing activation of the glycoprotein IIb/IIIa complex, reducing platelet aggregation.
Following oral administration:
Bleeding is associated with the use of clopidogrel and can occur at virtually any site. The risk of bleeding is multifactorial and includes concurrent use of multiple agents that affect clotting. Monitor carefully.
Caution is advised in patients over the age of 75, or those with a propensity to bleed. Bleeding should be suspected if patients become hypotensive, even if there are no obvious external signs of hemorrhage.